Dr. Anna Sureda, Head of the Onco-Hematology Service at Blood Cell Barcelona, discusses the results of the ECHELON-1 study of brentuximab vedotin as a frontline treatment for late-stage Hodgkin lymphoma.
The study, which concluded in 2017, found a significant benefit for those patients receiving brentuximab vedotin. The follow-up data presented at ASH 2020, representing a median follow-up of over 55 months, supported the results of the original study, suggesting that the addition of brentuximab vedotin is beneficial for those recently diagnosed with late-stage Hodgkin lymphoma.
HL is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases. It is an uncommon cancer with about 8,500 new cases reported in the U.S. each year.
The onset of Hodgkin lymphoma occurs most frequently in young adults (age 15-35) followed by older adults (over age 55) and usually begins with the painless swelling of a lymph node in the upper body. HL can spread to multiple lymph node regions or lymphoid structures and associated systemic symptoms (weight loss > 10% of baseline, fevers, night sweats) are observed in about 20% of patients.
The disease is usually treated with autologous stem cell transplant or high-dose chemotherapy. In stage 3 Hodgkin lymphoma, the lymphoma is found in lymph node areas on both sides of the diaphragm or above the diaphragm and in the spleen. In stage 4 Hodgkin lymphoma, it has spread into at least one organ outside of the lymph system.
For more information about Hodgkin lymphoma and other rare cancers, visit checkrare.com/diseases/cancers/